1. Home
  2. SAM vs SNDX Comparison

SAM vs SNDX Comparison

Compare SAM & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Boston Beer Company Inc. (The)

SAM

Boston Beer Company Inc. (The)

HOLD

Current Price

$220.49

Market Cap

2.2B

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$20.33

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SAM
SNDX
Founded
1984
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Beverages (Production/Distribution)
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.8B
IPO Year
1995
2016

Fundamental Metrics

Financial Performance
Metric
SAM
SNDX
Price
$220.49
$20.33
Analyst Decision
Hold
Strong Buy
Analyst Count
10
12
Target Price
$243.78
$36.92
AVG Volume (30 Days)
152.4K
1.2M
Earning Date
02-24-2026
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
23.12
N/A
EPS
8.25
N/A
Revenue
$1,981,609,000.00
$111,304,000.00
Revenue This Year
N/A
$617.74
Revenue Next Year
$0.55
$115.66
P/E Ratio
$26.71
N/A
Revenue Growth
N/A
595.65
52 Week Low
$185.34
$8.58
52 Week High
$260.00
$22.73

Technical Indicators

Market Signals
Indicator
SAM
SNDX
Relative Strength Index (RSI) 63.97 48.11
Support Level $204.94 $19.71
Resistance Level $224.89 $21.02
Average True Range (ATR) 6.18 1.10
MACD 1.67 -0.17
Stochastic Oscillator 83.12 24.16

Price Performance

Historical Comparison
SAM
SNDX

About SAM Boston Beer Company Inc. (The)

Boston Beer is a top player in high-end malt beverages and adjacent categories in the US, with strong positions in craft beer, flavored malt beverages, hard cider, and hard seltzer. The bulk of volume and revenue is concentrated in four brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly. Beverages are produced using a hybrid model leveraging both in-house capacities and third-party breweries through contract arrangements. While the firm is required to use distributors to reach end markets, including retailers and on-premises operators, it also employs 500 internal sales representatives to educate the market about its products. The firm generates almost all sales in the US.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: